Clinical Significance of Elevated Neuron-Specific Enolase (NSE) Levels

Introduction to NSE

• NSE is a glycolytic enzyme enriched in neuronal cell bodies, making it a suitable marker of neuronal damage 1
• NSE is released following injury to neurons, with blood values likely correlating with the extent of anoxic-ischemic neurological injury 2

Clinical Applications of NSE

Post-Cardiac Arrest Prognostication

• NSE levels in CSF are proportional to traumatic brain injury (TBI) severity and associated with increased mortality rates in moderate or severe TBI 3, 1
• In post-cardiac arrest patients, NSE levels >33 μg/L at any time from day 1 to 3 appear to predict poor neurological outcome 4
• NSE levels are decreased in subjects treated with hypothermia over time (to 48 hours), suggesting its potential utility in monitoring treatment efficacy 4
• The discriminative value of NSE levels at 48-72 hours is higher than at 24 hours, with increasing NSE levels over time having additional value in predicting poor outcome 5

Limitations and Caveats

• NSE should not be used alone to predict neurological outcomes due to the possibility of high false-positive rates 6, 7, 8
• Laboratory standards for NSE measurement vary between centers, making comparison of absolute values difficult 7
• NSE is sensitive to hemolysis, which is a significant limitation for its use as a serum biomarker 1
• NSE is not specific to neuronal damage and can be produced by extra-central nervous system sources including hemolysis and erythrocytes 1, 7

Best Practice Recommendations

• When evaluating post-cardiac arrest patients, consider high serum values of NSE at 48 to 72 hours after cardiac arrest to support the prognosis of poor neurological outcome, but only when performed with other prognostic tests 7, 8
• Serial measurements showing persistently high or increasing NSE values provide more reliable prognostic information than single measurements 7, 5
• For post-cardiac arrest prognostication, use NSE as a confirmatory test rather than a primary method for estimating prognosis 7
• Take care when drawing blood samples for NSE measurement to avoid hemolysis, which can lead to false-positive results 7

Neuron-Specific Enolase as a Biomarker for Brain Damage

Primary Clinical Applications

• In non-TTM-treated patients, NSE thresholds for 0% false-positive rate ranged from 33 mcg/L to 90.9 mcg/L depending on timing (24-72 hours) 9
• In TTM-treated patients, thresholds varied more widely, from 25-151.5 mcg/L at 48 hours 9
• Optimal measurement timing: 48-72 hours post-ROSC provides higher discriminative value than 24-hour measurements 9
• Serial measurements: Increasing NSE values between any two time points (24h, 48h, 72h) strongly associate with poor outcome 9

Technical Limitations

• Laboratory variability: Measurement standards vary between centers and analyzers, making absolute value comparisons unreliable 9
• Extra-neuronal sources: Neuroendocrine tumors and hemolyzed samples produce non-neurological NSE elevation 9

Clinical Interpretation Caveats

• Threshold inconsistency: The 0% false-positive rate threshold varies dramatically (33-151.5 mcg/L) based on timing, temperature management, and measurement technique 9
• Incomplete kinetics knowledge: The exact temporal profile of NSE release and clearance post-injury remains incompletely characterized 9

Clinical Use of Neuron‑Specific Enolase (NSE) for Prognostication After Cardiac Arrest

Prognostic Value and Optimal Timing

• NSE is released after neuronal injury and correlates with the severity of anoxic‑ischemic brain damage, making it a key biomarker for predicting neurological outcomes after cardiac arrest. 10
• Measuring NSE at 48–72 hours after return of spontaneous circulation provides significantly higher discriminative ability than a 24‑hour measurement. 11

Thresholds for Poor Neurological Outcome

Patients Not Treated With Targeted Temperature Management (TTM)

• NSE concentrations > 33 µg/L during days 1‑3 predict poor outcome; other studies report thresholds of 47.6 µg/L at 24 h, 65.0 µg/L at 48 h, and 90.9 µg/L at 72 h. 12

Patients Treated With Targeted Temperature Management (TTM)

• Reported poor‑outcome thresholds are broader, ranging from 25‑151.5 µg/L at 48 h and 49.6‑151.4 µg/L at 24 h. 11

Serial Measurements vs. Single Values

• An increase in NSE between any two time points (24 h, 48 h, 72 h) is strongly associated with poor neurological outcome and is more predictive than a single absolute value. 10

Requirement for Multimodal Integration

• NSE must be interpreted only after ≥72 hours post‑arrest and combined with bilateral absence of N20 somatosensory evoked potentials, EEG findings, brain imaging, and clinical examination before prognostic decisions are made. 13
• The American Heart Association classifies the use of NSE alone for prognostication as Class III (Harm), indicating it can cause premature withdrawal of life‑support. 13

Pre‑analytical and Analytical Limitations

Hemolysis

• Hemolysis releases NSE from red blood cells, producing false‑positive elevations; sample quality must be verified before interpretation. 13
• NSE assays are highly sensitive to hemolysis, so careful blood‑draw technique is essential. 13

Laboratory Variability

• Significant inter‑laboratory variability exists among NSE measurement platforms, making absolute published thresholds unreliable; institutions should rely on their own reference ranges and trend analyses. 10

Non‑Neurological Sources of Elevation

• NSE can be elevated by extra‑neuronal conditions such as neuroendocrine tumors, small‑cell lung carcinoma, and other APUD‑type tumors, which may confound interpretation in cardiac‑arrest patients. 12

Practical Clinical Algorithm (Key Steps)

• Verify sample integrity and exclude hemolysis before interpreting NSE results. 13
• Perform NSE measurement at 48–72 hours post‑ROSC for optimal discriminative value. 11
• Obtain serial NSE measurements and assess trends rather than relying on a single value. 10
• Integrate NSE results with multimodal neuro‑prognostic tools (SSEP, EEG, imaging, clinical exam) before making any withdrawal‑of‑life‑support decisions. 13
• Do not use NSE as a standalone prognostic marker. 13